Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NYSE:CVM NASDAQ:EDSA NASDAQ:INKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$13.32+5.2%$10.68$2.31▼$14.70$64.20M-0.5746,848 shs41,602 shsCVMCEL-SCI$10.43+12.0%$6.28$1.98▼$39.30$71.78M0.54373,970 shs514,864 shsEDSAEdesa Biotech$2.36-1.3%$2.22$1.55▼$5.00$16.61M0.121,131 shs665 shsINKTMiNK Therapeutics$14.24-3.9%$15.54$4.56▼$76.00$64.37M0.33122,560 shs51,696 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics0.00%-1.04%+24.25%+43.23%+225.99%CVMCEL-SCI0.00%+9.56%+10.37%+320.56%-67.81%EDSAEdesa Biotech0.00%-1.67%+10.28%+18.59%-47.56%INKTMiNK Therapeutics0.00%-4.43%-3.26%+98.47%+75.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOEPCoeptis Therapeutics0.7536 of 5 stars0.03.00.00.03.51.70.0CVMCEL-SCI0.4654 of 5 stars0.04.00.00.00.01.70.6EDSAEdesa Biotech2.1564 of 5 stars2.05.00.00.03.31.70.6INKTMiNK Therapeutics2.8243 of 5 stars3.35.00.00.01.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/ACVMCEL-SCI 0.00N/AN/AN/AEDSAEdesa Biotech 4.00Strong Buy$5.00111.86% UpsideINKTMiNK Therapeutics 2.60Moderate Buy$37.50163.34% UpsideCurrent Analyst Ratings BreakdownLatest EDSA, INKT, CVM, and COEP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.61 per shareN/ACVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-201.73%-108.46%N/ACVMCEL-SCI-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/AEDSAEdesa Biotech-$6.17M-$1.32N/AN/AN/AN/A-162.95%-60.33%N/AINKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)Latest EDSA, INKT, CVM, and COEP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COEPCoeptis TherapeuticsN/A-$1.17N/A-$1.17N/A$0.20 million8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/A8/8/2025Q3 2025EDSAEdesa Biotech-$0.26-$0.25+$0.01-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.830.83CVMCEL-SCI0.661.071.09EDSAEdesa BiotechN/A18.9618.96INKTMiNK TherapeuticsN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%CVMCEL-SCI12.08%EDSAEdesa Biotech5.50%INKTMiNK Therapeutics2.87%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%CVMCEL-SCI9.93%EDSAEdesa Biotech22.60%INKTMiNK Therapeutics22.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics24.82 million3.65 millionNot OptionableCVMCEL-SCI436.88 million64.67 millionOptionableEDSAEdesa Biotech207.04 million5.45 millionNot OptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataEDSA, INKT, CVM, and COEP HeadlinesRecent News About These CompaniesMiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $37.50 Consensus PT from BrokeragesAugust 26, 2025 | americanbankingnews.comMiNK Therapeutics (NASDAQ:INKT) Lowered to Strong Sell Rating by Wall Street ZenAugust 25, 2025 | marketbeat.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 25, 2025 | marketbeat.comB. Riley Reduces Earnings Estimates for MiNK TherapeuticsAugust 24, 2025 | marketbeat.comB. Riley Forecasts Weaker Earnings for MiNK TherapeuticsAugust 23, 2025 | americanbankingnews.comMiNK Therapeutics (NASDAQ:INKT) Lowered to "Strong Sell" Rating by Zacks ResearchAugust 22, 2025 | marketbeat.comNew Strong Sell Stocks for August 22ndAugust 22, 2025 | zacks.comMiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks ResearchAugust 21, 2025 | americanbankingnews.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest UpdateAugust 17, 2025 | marketbeat.comMiNK Therapeutics (NASDAQ:INKT) Issues Earnings ResultsAugust 16, 2025 | marketbeat.comHC Wainwright & Co. Upgrades MiNK Therapeutics (INKT)August 16, 2025 | msn.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comMiNK Therapeutics Reports Q2 2025 Milestones and FinancialsAugust 15, 2025 | msn.comMiNK Therapeutics Extends Cash RunwayAugust 14, 2025 | aol.comAMiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnershipsAugust 14, 2025 | msn.comMiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last yearAugust 14, 2025 | msn.comMiNK INKT Q2 2025 Earnings Call TranscriptAugust 14, 2025 | fool.comMiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 ResultsAugust 14, 2025 | globenewswire.comMiNK Therapeutics (INKT) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short InterestAugust 2, 2025 | marketbeat.comMink Therapeutics Inc News (INKT) - Investing.comAugust 1, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEDSA, INKT, CVM, and COEP Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$13.32 +0.66 (+5.21%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$13.34 +0.02 (+0.15%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.CEL-SCI NYSE:CVM$10.43 +1.12 (+12.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.46 +0.03 (+0.25%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Edesa Biotech NASDAQ:EDSA$2.36 -0.03 (-1.26%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$2.31 -0.05 (-2.33%) As of 08/29/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.MiNK Therapeutics NASDAQ:INKT$14.24 -0.58 (-3.91%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.70 +0.46 (+3.23%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
